Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis

INTRODUCTION: Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory CNS demyelinating disease. Two groups of monoclonal antibodies (mAbs) are used to prevent disease relapse, i.e., Food and Drug Administration (FDA)-approved mAbs (e.g., eculizumab satralizumab, inebilizumab),...

Descripción completa

Detalles Bibliográficos
Autores principales: Aungsumart, Saharat, Youngkong, Sitaporn, Dejthevaporn, Charungthai, Chaikledkaew, Usa, Thadanipon, Kunlawat, Tansawet, Amarit, Khieukhajee, Jedsada, Attia, John, McKay, Gareth J., Thakkinstian, Ammarin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110910/
https://www.ncbi.nlm.nih.gov/pubmed/37082442
http://dx.doi.org/10.3389/fneur.2023.1166490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110910/
https://www.ncbi.nlm.nih.gov/pubmed/37082442
http://dx.doi.org/10.3389/fneur.2023.1166490

Ejemplares similares